Literature DB >> 23666554

Differential responses to anticipation of reward after an acute dose of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) alone and in combination using functional magnetic resonance imaging (fMRI).

Louise E Curley1, Robert R Kydd, Ian J Kirk, Bruce R Russell.   

Abstract

RATIONALE: Functional magnetic resonance imaging (fMRI) studies have reported increased activation of the mesolimbic system in response to anticipation of rewarding stimuli. The anticipation of uncertain outcomes evokes activation in the amygdala, orbitofrontal cortex, inferior frontal gyrus and insula. Drugs known to effect dopaminergic and serotonergic neurons also alter regional activation.
OBJECTIVES: Benzylpiperazine (BZP) and/or trifluoromethylphenylpiperazine (TFMPP) have been recreationally used worldwide for more than a decade. BZP affects mainly dopaminergic neurons, while TFMPP has serotonergic effects.
METHODS: We investigated the effects of an acute dose of BZP, TFMPP or a combination of BZP and TFMPP on the anticipation of reward in a double-blind, placebo-controlled, crossover study using fMRI. An event-related gambling paradigm was completed by healthy controls 90 min after taking an oral dose of either BZP (200 mg), TFMPP (either 50 or 60 mg), BZP + TFMPP (100 + 30 mg) or placebo.
RESULTS: After giving BZP, the anticipation of a $4 reward decreased the activation of the inferior frontal gyrus, insula and occipital regions in comparison to placebo. TFMPP increased the activation of the putamen but decreased the activity in the insula relative to placebo. When BZP and TFMPP were given in combination, activation of the rolandic operculum occurred. The magnitude of reward also affected neural correlates.
CONCLUSION: We propose that the effects of BZP and TFMPP on dopaminergic and serotonergic circuitry, respectively, reflect regional changes. The dopaminergic effects of BZP appear to increase positive arousal and subsequently reduce the response to uncertainty, while TFMPP appears to alter the response to uncertainty by increasing emotional responses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23666554     DOI: 10.1007/s00213-013-3128-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  70 in total

1.  Tracking the hemodynamic responses to reward and punishment in the striatum.

Authors:  M R Delgado; L E Nystrom; C Fissell; D C Noll; J A Fiez
Journal:  J Neurophysiol       Date:  2000-12       Impact factor: 2.714

2.  Anticipation of increasing monetary reward selectively recruits nucleus accumbens.

Authors:  B Knutson; C M Adams; G W Fong; D Hommer
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

Review 3.  Opponent interactions between serotonin and dopamine.

Authors:  Nathaniel D Daw; Sham Kakade; Peter Dayan
Journal:  Neural Netw       Date:  2002 Jun-Jul

4.  Full substitution of the discriminative cue of a 5-HT(1A/1B/2C) agonist with the combined administration of a 5-HT(1B/2C) and a 5-HT(1A) agonist.

Authors:  F Miranda; G Orozco; D N Velázquez-Martínez
Journal:  Behav Pharmacol       Date:  2002-07       Impact factor: 2.293

Review 5.  Inhibition and the right inferior frontal cortex.

Authors:  Adam R Aron; Trevor W Robbins; Russell A Poldrack
Journal:  Trends Cogn Sci       Date:  2004-04       Impact factor: 20.229

6.  The subjective experience of pain: where expectations become reality.

Authors:  Tetsuo Koyama; John G McHaffie; Paul J Laurienti; Robert C Coghill
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

7.  The neural basis of financial risk taking.

Authors:  Camelia M Kuhnen; Brian Knutson
Journal:  Neuron       Date:  2005-09-01       Impact factor: 17.173

8.  Dissociation of neural regions associated with anticipatory versus consummatory phases of incentive processing.

Authors:  Daniel G Dillon; Avram J Holmes; Allison L Jahn; Ryan Bogdan; Lawrence L Wald; Diego A Pizzagalli
Journal:  Psychophysiology       Date:  2007-09-10       Impact factor: 4.016

9.  Evidence for addiction-like behavior in the rat.

Authors:  Véronique Deroche-Gamonet; David Belin; Pier Vincenzo Piazza
Journal:  Science       Date:  2004-08-13       Impact factor: 47.728

10.  Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist?

Authors:  P Schoeffter; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

View more
  4 in total

1.  Acute effects of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) using functional magnetic resonance imaging (fMRI) and the Stroop task--a pilot study.

Authors:  Louise E Curley; Rob R Kydd; Michelle C Robertson; Avinesh Pillai; Nicolas McNair; HeeSeung Lee; Ian J Kirk; Bruce R Russell
Journal:  Psychopharmacology (Berl)       Date:  2015-04-19       Impact factor: 4.530

2.  Peripheral Serotonin 1B Receptor Transcription Predicts the Effect of Acute Tryptophan Depletion on Risky Decision-Making.

Authors:  Paul Faulkner; Federico Mancinelli; Patricia L Lockwood; Mar Matarin; Raymond J Dolan; Nick W Wood; Peter Dayan; Jonathan P Roiser
Journal:  Int J Neuropsychopharmacol       Date:  2017-01-01       Impact factor: 5.176

Review 3.  An Update on the Implications of New Psychoactive Substances in Public Health.

Authors:  Ana Y Simão; Mónica Antunes; Emanuel Cabral; Patrik Oliveira; Luana M Rosendo; Ana Teresa Brinca; Estefânia Alves; Hernâni Marques; Tiago Rosado; Luís A Passarinha; Maristela Andraus; Mário Barroso; Eugenia Gallardo
Journal:  Int J Environ Res Public Health       Date:  2022-04-17       Impact factor: 4.614

Review 4.  Using pharmacological manipulations to study the role of dopamine in human reward functioning: A review of studies in healthy adults.

Authors:  Heather E Webber; Paula Lopez-Gamundi; Sydney N Stamatovich; Harriet de Wit; Margaret C Wardle
Journal:  Neurosci Biobehav Rev       Date:  2020-11-14       Impact factor: 8.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.